Against a backdrop of manufacturing prioritisation, Novo ... pen needles market. The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback